Bingyan Wang, DO
Internal Medicine · Millville, NJNPI 1306263819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,095 and has fallen 79.6% since, to $224 in 2025.
Across 123 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$488
- Lilly USA, LLC$223
- Amgen$177
- Novo Nordisk$176
- Exact Sciences$162
- Pfizer$145
- plus $878 from 22 others
What the payments were for
- Food & beverage$2,249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $488 |
| Lilly USA, LLC | 13 | $223 |
| Amgen(2 entities) | 10 | $177 |
| Novo Nordisk | 10 | $176 |
| Exact Sciences | 8 | $162 |
| Pfizer | 8 | $145 |
| Xeris Pharmaceuticals, Inc. | 6 | $129 |
| AstraZeneca | 6 | $98 |
| Dexcom, Inc. | 5 | $97 |
| Corcept Therapeutics | 4 | $71 |
| Amarin Pharma, Inc. | 3 | $53 |
| Tandem Diabetes Care, Inc. | 2 | $39 |
| Kyowa Kirin, Inc. | 2 | $36 |
| GSK | 2 | $36 |
| Novartis | 2 | $34 |
| Pulmonx Corporation | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Bayer | 1 | $25 |
| Almatica Pharma LLC | 1 | $25 |
| Halozyme Inc | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Dermavant Sciences, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| IBSA Pharma Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
How this compares
$2,249 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 26 | $26,714 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $23,000 |
| JardianceEmpagliflozin | 24 | $20,602 |
| Repatha SureclickEvolocumab | 11 | $6,756 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,063 |
| Rosuvastatin Calcium | 41 | $1,039 |
| Losartan Potassium | 80 | $824 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $686 |
| Atorvastatin Calcium | 72 | $632 |
| Duloxetine Hcl | 25 | $572 |
| Metformin Hcl ErMetformin Hcl | 64 | $550 |
| Levothyroxine Sodium | 47 | $527 |
| Tizanidine Hcl | 12 | $514 |
| Pantoprazole Sodium | 37 | $473 |
| Gabapentin | 33 | $450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $223 | $26,71426 claims |
| GSKTrelegy Ellipta | $36 | $23,00029 claims |
| Boehringer IngelheimJardiance | $21 | $20,60224 claims |
| Almatica Pharma LLCSertraline Hcl | $25 | $7915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Millville
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.